A first-in-human phase 1 study of proxalutamide (GT0918), a dual MOA androgen receptor blocker in patients with advanced CRPC.

Tie Zhou,Weidong Xu,Chuangliang Xu,Xu Gao,Jianguo Hou,Shancheng Ren,Bo Yang,Guolan Wei,Ye Sun,Chunyun Chen,Chuangxing Guo,Youzhi Tong,Karl Zhou,Yinghao Sun

A first-in-human phase 1 study of proxalutamide (GT0918), a dual MOA androgen receptor blocker in patients with advanced CRPC.

2017

Tie Zhou
Weidong Xu
Chuangliang Xu
Xu Gao
Jianguo Hou
Shancheng Ren
Bo Yang
Guolan Wei
Ye Sun
Chunyun Chen
Chuangxing Guo
Youzhi Tong
Karl Zhou
Yinghao Sun

e16511Background: Proxaluatmide is a novel dual MOA androgen receptor (AR) blocker with potent AR antagonist activity and capability to down-regulate AR level. We conducted a first-in-human phase 1...

Keywords:

Proxalutamide
Androgen receptor
Cancer research
Pathology
Medicine
Antagonist
first in human
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations